AAP updates pediatric sleep apnea guidelines

AAP updates pediatric sleep apnea guidelines
AAP updates pediatric sleep apnea guidelines

HealthDay News -- The American Academy of Pediatrics (AAP) has released revised recommendations for the diagnosis and management of obstructive sleep apnea syndrome (OSAS) in children and adolescents. 

Carole L. Marcus, M.B.B.Ch., from the AAP's Subcommittee on Obstructive Sleep Apnea Syndrome, and colleagues based the new recommendations on a literature review of 350 relevant articles published from 1999 to 2010, most of which were considered level II to IV grade evidence. The revised clinical practice guidelines were published online in Pediatrics.

The new guidelines state that all children and adolescents be screened for snoring, and that polysomnography be performed in those with snoring and symptoms or signs of OSAS. Adenotonsillectomy is the first-line treatment of choice for patients with adenotonsillar hypertrophy, with reevaluation recommended postoperatively to determine whether further treatment is required.

If adenotonsillectomy is not performed or if OSAS persists postoperatively, continuous positive airway pressure (CPAP) is recommended as a treatment. For overweight or obese patients, weight loss is recommended in addition to other therapy.

For children with mild OSAS in whom adenotonsillectomy is contraindicated or for mild postoperative OSAS, intranasal corticosteroids should be considered.

"There is a great need for further research into the prevalence of OSAS, sequelae of OSAS, best treatment methods, and the role of obesity," Marcus and colleagues wrote.


References

  1. Marcus CL et al. Pediatrics. 2012; doi:10.1542/peds.2012-1671.
This article originally appeared here.

Related Slideshows

More in Web Exclusives

FDA clears HbA1c test for diabetes diagnosis

FDA clears HbA1c test for diabetes diagnosis

Previously, the FDA has only allowed manufacturers to market HbA1c tests as tools for monitoring blood glucose, not diagnosis.

Stroke costs expected to double by 2030

Stroke costs expected to double by 2030

Higher stroke prevalence in an aging population brings total projected stroke costs to $240.67 billion by 2030.

Fish oil may benefit insulin sensitivity

Fish oil may benefit insulin sensitivity

Long-chain fatty acids in fish oil boost circulating adiponectin levels.